ESCRS - Preloaded Tissue Changing the Face of Transplant Surgery ;
ESCRS - Preloaded Tissue Changing the Face of Transplant Surgery ;

Preloaded Tissue Changing the Face of Transplant Surgery

Eye banks of the future draw nearer as technological advances strengthen surgeon skill. Dermot McGrath reports.

Preloaded Tissue Changing the Face of Transplant Surgery
Dermot McGrath
Dermot McGrath
Published: Thursday, December 1, 2022

Using pre-cut and preloaded donor graft tissue for endothelial keratoplasty (EK) can significantly reduce operating time, minimise intraoperative tissue manipulation, and facilitate access to EK procedures for less experienced surgeons, according to Stefano Ferrari PhD.

“We have seen a major evolution in recent years with the shift from full-graft penetrating keratoplasty (PK) procedures towards selective lamellar and endothelial procedures. This has led to an increased demand for eye bank prepared and preloaded tissues for Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK),” he said.

Speaking to EuroTimes, Dr Ferrari said there are several advantages to using preloaded tissue from eye banks.

“The first advantage is the reduction in surgery time, as the surgeon no longer has to prepare the tissue in the operating room,” he explained. “In many hospitals in Italy, there is a specific time slot allocated for the use of the surgery room. Sometimes the ophthalmology department has its own surgery room, but often they need to use shared platforms and all the ophthalmology procedures have to be performed in an allocated amount of time. So, it stands to reason that if you reduce the time of every single procedure, then you can perform more procedures in the same amount of time.”

The next clear benefit of using preloaded tissue is it significantly reduces the learning curve for surgeons who perform only occasional corneal transplants and for whom the more technically challenging DMEK procedure can be daunting.

“The learning curve of DMEK procedure is quite steep, and the more cases you do, the better you become. But it remains technically difficult, and preparing the tissue is stressful for many surgeons,” Dr Ferrari remarked. “By contrast, our technicians in the eye bank prepare up to 10 tissues for DMEK or DSAEK a day, so they have perfected their skills over time. This is another advantage—because the technicians are so used to performing the tasks, the quality of the tissue is much better.”

Having preloaded tissue also removes the risk of stripping Descemet’s membrane in the operating room and compromising the surgery if not performed correctly.

“It is a delicate procedure and a lot can potentially go wrong when stripping the endothelium. This can mean a postponed surgery and a wasted cornea. And even if you have a backup cornea, there is obviously an extra cost involved in having to use that as well. Having the tissue ready to be transplanted makes life a lot easier and reduces a lot of the stress for the surgeon,” he said.

With demand increasing for preloaded tissue, Dr Ferrari believes better delivery devices and storage techniques will continue to drive improved efficiency and outcomes in the future.

“There are a lot of different delivery systems currently available for graft delivery in DMEK, for instance, but none of them are optimal in all aspects of the procedure. We need better and smoother delivery methods, more transparency for easier handling, and greater visibility during the graft transfer.

There are many issues that can be improved to make the devices even better,” he said.

Dr Ferrari believes the eye bank of the near future will also evolve to take account of advances in bioengineering and cellular technologies.

“I can see eye bank services expanding to the point where we have laboratories incorporated that work with cells as well as tissues. So, eye banks will offer cellular therapies under good manufacturing practices (GMP) where cells can be amplified and manipulated for transplantation—or artificial corneas for patients with advanced keratoconus. There are so many possibilities, and it’s exciting to see how it will evolve in the coming years,” he concluded.

Dr Ferrari presented at the 40th Congress of the ESCRS in Milan.

Stefano Ferrari PhD currently serves as Head of Research and Development at the Veneto Eye Bank Foundation in Venice, Italy (http://www.fbov.org). stefano.ferrari@fbov.it

Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;